Ossio: Funding, Investors & Team (Sep 2026)

OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents a breakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind. Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now.

Ossio has raised $106M across 3 rounds on record. The most recent is an undisclosed round of $40.0M announced in Feb 2026.

Ossio's most recent funding round on record is an undisclosed round of $40.0M, announced in Feb 2026.

FundedIQ lists Orahn Preiss Bloom (Founder) at Ossio.

Ossio is based in Woburn, Massachusetts, United States.

Ossio is in the 51-100 employee band.

Ossio's latest round of $40.0M is above the $4.8M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.